By identifying specific chromosomal abnormalities, karyotyping can help in selecting targeted therapies. For example, patients with CML who have the Philadelphia chromosome may benefit from tyrosine kinase inhibitors like imatinib. Additionally, karyotyping can monitor the effectiveness of treatment by checking for the persistence or disappearance of chromosomal abnormalities.
